Datopotamab Deruxtecan Recommended for Approval in the EU
Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody drug conjugate developed by Daiichi Sankyo and AstraZeneca, has been recommended for approval...
Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody drug conjugate developed by Daiichi Sankyo and AstraZeneca, has been recommended for approval...
CervoMed provided an update on its Phase 2b RewinD-LB trial for neflamapimod in dementia with Lewy bodies (DLB). The...
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of Merck’s CAPVAXIVE, a 21-valent...
Eisai and Biogen provided an update on the European Union’s regulatory review of lecanemab, a treatment for early-stage Alzheimer’s...
Rapid Medical has enrolled the first patient in its COGNITIVE study, investigating the link between mechanical thrombectomy using their...
New data from the Tufts Center for the Study of Drug Development (CSDD) reveals a correlation between decentralized clinical...
Adial Pharmaceuticals completed a pharmacokinetic study of AD04, a selective serotonin-3 receptor antagonist for Alcohol Use Disorder (AUD), and...
Sermonix Pharmaceuticals announced published results from a secondary endpoint analysis of its Phase 2 ELAINE-1 study of lasofoxifene in...
Dewpoint Therapeutics has nominated DPTX3496, its second drug development candidate. DPTX3496 is an oral small molecule designed to treat...
4D Molecular Therapeutics will present 52-week interim data from the Phase 2b portion of its PRISM clinical trial evaluating...